Article Details

European Commission Approves Pfizer's ELREXFIO for Relapsed and Refractory Multiple Myeloma

Retrieved on: 2023-12-11 15:02:00

Tags for this article:

Click the tags to see associated articles and topics

European Commission Approves Pfizer's ELREXFIO for Relapsed and Refractory Multiple Myeloma. View article details on hiswai:

Excerpt

NEW YORK - Pfizer Inc. today announced the European Commission has granted conditional marketing authorization for ELREXFIO .

Article found on: www.marketscreener.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo